The Tissue Diagnostic Market size was valued at USD 5.21 Bn. in 2022 and the total revenue is expected to grow by 5.8% from 2023 to 2029, reaching nearly USD 7.73 Bn. Tissue diagnostics which are also known as anatomical or histology pathology are used in various techniques to diagnose diseases based on tissues from organs and tumors. Tissue Diagnostics are part of an individual patients clinical recoed access. Advancement such as tissue based companion diagnostics, automatation and the uses of the digital solution at laboratories are driving the Tissue Diagnostic market growth. Several technologies with great potentials are significantly driving the Tissue Diagnostic market. The advances in Tissue Diagnostics by adding 3D diagnosis, as well as 3D bioprinting, combined with automated pathology have the potential of being widely employed by several pathologies in near future. Self Learning AI based software are goin to play an important role in the Tissue Diagnostics segment. Besides the liquid biopsies and the next generation sequencing will have the potential in to bring a revolution in Tissue Diagnostic market. According to World Health Organization, Cancer is one of the leading cause death worldwide, accounting for nearly 10 million deaths in 2020, Tissue Diagnostics capture the biological environment of tumours, the market has experienced a significant demand and has profitable growth potential over forecasted period. Increasing adaptation rate of automated tissue based diagnostic tools several research institutes are able to diagnose malignancies at faster rate. These automated Tissue Diagnostic platform uses a high-quality video system combined with AI to assess specimens and to create a gross report 93% faster than human technicians with 43% more accurate. For Instance, in September 2019, the West Clinic Cancer Center and F. Hoffmann-La Roche Ltd. came together to use Roche's BenchMark ULTRA Automated Advanced Staining System to enhance patient treatment. To promote quicker tumour diagnosis, this technology is employed for in situ hybridization or immunohistochemistry testing.
Scope of the Report:The report provides a comprehensive analysis of the global Tissue Diagnostic Market. The report estimates the Tissue Diagnostic Market, in terms of USD value from 2023 to 2029. In order to identify potential investment pockets, this report gives an analytical representation of the Tissue Diagnostic industry together with current trends and future forecasts. The report includes a thorough analysis of the market share for Tissue Diagnostic as well as data on important drivers, restraints, and opportunities. A quantitative analysis of the existing market is done from 2023 to 2029 to show the potential for market growth across the globe. In addition, Porter's five forces study demonstrates the market power of both buyers and providers. The research offers a thorough analysis of the worldwide Tissue Diagnostic market based on the level of competition and how it will develop over the forecast period.To know about the Research Methodology :- Request Free Sample Report
Tissue Diagnostic Market Dynamics:The market for Tissue Diagnostics is driven by an increase in revenue creation due to key companies' increased focus on creating sophisticated tissue-based companion diagnostic tests. For instance, Agilent's PD-L1 IHC 22C3 pharmDx assay, which is used to detect non-small cell lung cancer, was approved by the FDA in April 2019. An immunohistochemistry assay of high quality was created in collaboration with Merck. The workflow in anatomic pathology is still moving from highly manual to automated, which has increased the need for new solutions. The problems associated with the shortage of pathologists have been successfully addressed by the incorporation of bioinformatics, process standardisation in pathology laboratories, and automated molecular diagnostic technologies. The increase in the awareness campaings, technological research advancements and improving Healthcare infrastructure is paving the way for better opportunity in the Tissue Diagnostic market. The major factor that are driving the growth of the Tissue Diagnostic market are growing incidence of organ donation, cancer and transplant movement and the rising acceptance of the personalize medicines and companion diagnostics where each patient is being treated individually and thus the advance diagnostics plays a huge role. Though the Tissue Diagnostic market is dominated by North America and Europe, the market is shifting its focus on the Asian market particularly India. The Indian Diagnostic market has been growing at 18-25 percent and currently is estimated to be worth of rs 45,200 crore. As stated earlier, due to the higher incidence of cancer globally, growing awareness of genetics and heritability of cancers have been the key drivers fuelling the growth of the Tissue Diagnostic market worldwide. Also, a rise in the compananion diagnostics for the targeted therapies in the areas like transplant pathology and icreased organ transplantation and increased use of Biomakers for the disease diagnosis are propelling the growth of the Tissue Diagnostic Market. The Tissue Diagnostic represents overall 8-10 percent of the total IVD market. Not only the rising incidence of cancer, but non-neoplastic acquired conditions like inflammatory bowel diseases, thalassemia malabsorption syndromes have led to the growth of the tissue Diagnostic market. The lack of Tissue Diagnostics in chronic wound care has lead to uncertainity in the detection of chronic inflammation. Despite the evidence, clinicians report that incorporating Tissue Diagnostics into every day practice is challenging across the globe. As a result of change from traditional pathology to digital pathology, practitioners now give priority to urgent patients, speed up test results, and improve patient outcomes. For instance, in May 2019, Alverno Laboratories and Royal Phillips deployed Philips' IntelliSite Pathology Solution in their clinical labs to improve the effectiveness, calibre, and patient safety of the labs. The popularity of digital pathology solutions consequently increases. The increased technical performance of the assays, which lowers the cost of reagents and assay time, is helping automated Tissue Diagnostics become more popular. The demand for automation in Tissue Diagnostic systems is additionally exacerbated by the management of massive amounts of data and the scarcity of qualified pathologists. One breakthrough in tissue diagnostics is the automation of staining equipment. Another is the use of new platforms like digital immunohistochemistry (IHC). Also emerging in the realm of tissue diagnostics is an enhanced laboratory information system (LIS). The growth of the tissue diagnostics market will be influenced by the creation of end-to-end integrated workflow solutions. Anatomic pathology LIS (APLIS) providers and instrument distributors in developing nations can work together to accomplish this.
Tissue Diagnostic Market Segment Analysis:By Product Type, Immunohistochemistry (IHC), which is widely used in clinical research and the development of cancer diagnostics and therapies had the greatest revenue share in 2022. IHC is usually chosen over traditional enzyme staining methods because it explicitly identifies differences between various tumour types. While only a small subset of tumour tissue structures, enzymes, and proteins are detected by standard methods. Over the forecasted period, digital pathology is anticipated to increase at the quickest rate. One of the main causes fueling the segment's growth is a rise in the usage of whole-slide imaging (WSI) among pathologists. To further help the cancer diagnosis and offer useful clinical measurements for tumours, WSI extracts particular aspects of tumours and quantifies each component of these traits. Due to new and innovative product, several vendors are significantly contributing to use of digital technology. For instance, in March 2019, in collaboration with OptraSCAN, Nikon Instruments Inc. unveiled the OS-15-N, a digital slide scanning system. Similar to this, HealthCare Global Enterprises Ltd. launched Philips' FDA-approved IntelliSite Pathology Solution throughout India in April 2019. By Application Insights, Increasing incidence rates of breast cancer worldwide, which are brought on by a rise in inheritance and family history, the breast cancer category accounted for the highest share in terms of revenue in 2019. Additionally, number of research projects supported by public and commercial institutions continue to advance the creation of efficient breast cancer diagnostic tools. The market for tissue diagnostics for this application is rapidly growing. For instance, the CanAssist-Breast test was approved by a research study that was released in March 2019. It is an immunohistochemical prognostic test to assess the likelihood of recurrence in the early stages of hormone-receptor-positive breast cancer. By Application, extensive use of Tissue Diagnostic solutions, hospital segment dominated the end-use category in terms of revenue creation in 2022. The use of tissue-based diagnostic testing tools by doctors is replacing more and more traditional testing methods. This is due to the fact that Tissue Diagnostic tests take less time than traditional techniques. Additionally, hospitals are implementing agreement models for more accurate disease diagnosis, which is fueling segment growth. For instance, the Taipei Veterans General Hospital (Taiwan) and Philips secured a contract in August 2019 to implement the latter's IntelliSite Pathology Solution in the hospital. This agreement changed pathological tissue inspection in the hospital to digital diagnoses.
Tissue Diagnostic Market Regional Insights:North America will dominate the Tissue Diagnostic market through the forecast period. One of the main factors expected to fuel the growth of the Tissue Diagnostic market in numerous government initiatives e to reduce the prevalence of cancer and increase the need for cancer diagnosis aids. Human tissue is a key component of the creation of novel tests in personalised medicine. The use of tissue diagnostics is being further fueled by the growth of personalised medicine due to the increased acceptance of sequencing technologies and healthcare IT systems in clinical workflow.. Increased availability to various Tissue Diagnostic tests offered by foreign companies, Asia Pacific is predicted to see tremendous growth rate in the near future. For instance, in April 2019, Genecast and HalioDx SAS inked a contract for the sale of the latter's Immunoscore diagnostic assay in China. Due to this programme, there are now more Chinese colon cancer patients who can get this product. In India, hospitals with increased focus on oncology is likely to fuel the market growth of the Tissue Diagnostics segment. Large network labs are also consolidating the segment with the availability of the quality test result and the early introduction of the newer diagnostic test that are made available across all geographical areas.
Tissue Diagnostic Market Scope: Inquire before buying
Tissue Diagnostic Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2017 to 2022 Market Size in 2022: US $ 5.21 Bn. Forecast Period 2023 to 2029 CAGR: 5.8% Market Size in 2029: US $ 7.73 Bn. Segments Covered: by Product Type 1. Kit 2.Instrument or Device by Technology Insight 1.Immunohistochemistry 2.Instruments 3.Slide Staining Systems 4.Tissue Microarrays 5.Tissue Processing Systems 6.Slide Scanners 7.Other Products 8.Consumables 9.Antibodies 10.Reagents 11.Kits 12.In Situ Hybridization 13.Instruments 14.Consumables 15.Software 16.Primary and Special Staining 17.Digital Pathology and Workflow 18.Whole Slide Imaging 19.Image Analysis Informatics 20.Information Management System Storage & Communication 21.Anatomic Pathology 22.Instruments 23.Microtomes & Cryostat Microtomes 24.Tissue Processors 25.Automatic Strainers 26.Other Products 27.Consumables 28. Reagents & Antibodies 29.Probes & Kits 30.Others by Application Area 1.Breast Cancer 2.NSCLC 3.Prostate Cancer 4.Lymphoma by End-User 1.Hospitals 2.Research Laboratories 3.Others
Tissue Diagnostic Market, by RegionNorth America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)
Tissue Diagnostic Market, Key Players are:1. Bio SB (US) 2.Bio-Genex Laboratories (US) 3. Hologic Inc. (US) 4. Abbott Laboratories (US) 5.Danaher Corporation (US) 6.Bio-Rad Laboratories, Inc. (US) 7.BioMerieux (US) 8. Thermo Fisher Scientific Inc. (US) 9.Becton, Dickinson and Company (US) 10. Cell Signaling Technology, Inc. (US) 11. Agilent Technologies (US) 12. Caris Life Sciences (US) 13. Milestone Medical (US) 14.Leica Biosystems Nussloch GmbH (Germany) 15. SLEE Medical GmbH (Germany) 16. Merck KGaA (Germany) 17. Abcam plc (UK) 18. Koninklijke Philips N.V. (Netherlands) 19.QIAGEN N.V. (Netherlands) 20.F. Hoffmann-La Roche Ltd. (Switzerland) 21. TissueGnostics GmbH (Austria) 22.Histo-Line Laboratories (Italy) 23.Lumito AB (Sweden) 24.Sakura Finetek Japan Co., Ltd. (Japan) 25.Sekisui Medical Co., Ltd. (Japan) 26.Amos Scietific pty. Ltd (Australia) FAQs: 1. What is the study period of the market? Ans. The consumables sector is anticipated to hold the biggest market share in 2022. Consumables including reagents, kits, and antibodies are often utilised, which contributes to this segment's sizable market share. 2. What is the market size of the Tissue Diagnostic Market by 2029? Ans. The market size of the Tissue Diagnostic Market by 2029 is expected to reach at USD 7.73 Bn. 3. Which application segment is expected to have the largest share of the market? Ans. Based on application, breast cancer segment is expected to account for the largest share of the market. The high prevalence of the breast cancer and the presence of the screening programmes are the factors contributing to the large market share. 4. What was the market size of the Tissue Diagnostic Market in 2022? Ans. The market size of the Tissue Diagnostic Market in 2022 was valued at USD 5.21 Bn. 5. Who are the major key players contributing towards the growth of Tissue Diagnostic Market? Ans. Cell Signaling Technology, Inc , F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Thermo Fisher Scientific Inc.; Agilent Technologies.Siemens; Danaher;bioMérieux SA; QIAGEN; Becton, Dickinson and Company; Merck KGaA; GE Healthcare; BioGenex;.; Bio SB; DiaGenic ASA.
1. Global Tissue Diagnostic Market: Research Methodology 2. Global Tissue Diagnostic Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Tissue Diagnostic Market 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Tissue Diagnostic Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11. Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12 COVID-19 Impact 4. Global Tissue Diagnostic Market Segmentation 4.1 Global Tissue Diagnostic Market, by Product Type (2023-2029) • Kit • Instrument or Device 4.2 Global Tissue Diagnostic Market, by Technolgy Insights (2023-2029) • Immunohistochemistry • Instruments • Slide Staining Systems • Tissue Microarrays • Tissue Processing Systems • Slide Scanners • Other Products • Consumables • Antibodies • Reagents • Kits • In Situ Hybridization • Instruments • Consumables • Software • Primary and Special Staining • Digital Pathology and Workflow • Whole Slide Imaging • Image Analysis Informatics • Information Management System Storage & Communication • Anatomic Pathology • Instruments • Microtomes & Cryostat Microtomes • Tissue Processors • Automatic Strainers • Other Products • Consumables • Reagents & Antibodies • Probes & Kits • Others 4.3 Global Tissue Diagnostic Market, by Application Area (2023-2029) • Breast Cancer • NSCLC • Prostate Cancer • Lymphoma 5. North America Tissue Diagnostic Market(2023-2029) 5.1 North America Tissue Diagnostic Market, by Product Type (2023-2029) • Kit • Instrument or Device 5.2 North America Tissue Diagnostic Market, by Technolgy Insights (2023-2029) • Immunohistochemistry • Instruments • Slide Staining Systems • Tissue Microarrays • Tissue Processing Systems • Slide Scanners • Other Products • Consumables • Antibodies • Reagents • Kits • In Situ Hybridization • Instruments • Consumables • Software • Primary and Special Staining • Digital Pathology and Workflow • Whole Slide Imaging • Image Analysis Informatics • Information Management System Storage & Communication • Anatomic Pathology • Instruments • Microtomes & Cryostat Microtomes • Tissue Processors • Automatic Strainers • Other Products • Consumables • Reagents & Antibodies • Probes & Kits • Others 5.3 North America Tissue Diagnostic Market, by Application Area (2023-2029) • Breast Cancer • NSCLC • Prostate Cancer • Lymphoma 5.4 North America Tissue Diagnostic Market, by Country (2023-2029) • United States • Canada • Mexico 6. Europe Tissue Diagnostic Market (2023-2029) 6.1. Europe Tissue Diagnostic Market, by Product Type (2023-2029) 6.2. Europe Tissue Diagnostic Market, by Technolgy Insights (2023-2029) 6.3. Europe Tissue Diagnostic Market, by Application Area (2023-2029) 6.4. Europe Tissue Diagnostic Market, by Country (2023-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Tissue Diagnostic Market (2023-2029) 7.1. Asia Pacific Tissue Diagnostic Market, by Product Type (2023-2029) 7.2. Asia Pacific Tissue Diagnostic Market, by Technolgy Insights (2023-2029) 7.3. Asia Pacific Tissue Diagnostic Market, by Application Area (2023-2029) 7.4. Asia Pacific Tissue Diagnostic Market, by Country (2023-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Tissue Diagnostic Market (2023-2029) 8.1 Middle East and Africa Tissue Diagnostic Market, by Product Type (2023-2029) 8.2. Middle East and Africa Tissue Diagnostic Market, by Technolgy Insights (2023-2029) 8.3. Middle East and Africa Tissue Diagnostic Market, by Application Area (2023-2029) 8.4. Middle East and Africa Tissue Diagnostic Market, by Country (2023-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Tissue Diagnostic Market (2023-2029) 9.1. South America Tissue Diagnostic Market, by Product Type (2023-2029) 9.2. South America Tissue Diagnostic Market, by Technolgy Insights (2023-2029) 9.3. South America Tissue Diagnostic Market, by Application Area (2023-2029) 9.4. South America Tissue Diagnostic Market, by Country (2023-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1 Bio SB (US) 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Bio-Genex Laboratories (US) 10.3. Hologic Inc. (US) 10.4. Abbott Laboratories (US) 10.5. Danaher Corporation (US) 10.6. Bio-Rad Laboratories, Inc. (US) 10.7. BioMerieux (US) 10.8. Thermo Fisher Scientific Inc. (US) 10.9. Becton, Dickinson and Company (US) 10.10. Cell Signaling Technology, Inc. (US) 10.11. Agilent Technologies (US) 10.12. Caris Life Sciences (US) 10.13. Milestone Medical (US) 10.14. Leica Biosystems Nussloch GmbH (Germany) 10.15. SLEE Medical GmbH (Germany) 10.16. Merck KGaA (Germany) 10.17. Abcam plc (UK) 10.18. Koninklijke Philips N.V. (Netherlands) 10.19. QIAGEN N.V. (Netherlands) 10.20. F. Hoffmann-La Roche Ltd. (Switzerland) 10.21. TissueGnostics GmbH (Austria) 10.22. Histo-Line Laboratories (Italy) 10.23. Lumito AB (Sweden) 10.24. Sakura Finetek Japan Co., Ltd. (Japan) 10.25. Sekisui Medical Co., Ltd. (Japan) 10.26. Amos Scietific pty. Ltd (Australia)